| 标题 |
Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)? |
| 网址 | |
| DOI | |
| 其它 |
期刊:Leukemia 作者:Yang S, Kay NE, Shi M, Hanson CA, Gale RP 出版日期:2022-09-13 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人或该文件上传人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)